Results 11 to 20 of about 3,185 (155)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts

open access: yesAllergy, Asthma & Clinical Immunology, 2021
Background Mepolizumab and benralizumab are biologics approved for severe eosinophilic asthma. Mepolizumab is an anti-interlukin-5 (IL-5) antibody while benralizumab is an anti-interleukin-5 receptor alpha (IL-5Rα) antibody targeting the IL-5 receptor on
Arian Ghassemian   +3 more
doaj   +1 more source

A systematic review and integrated analysis of biologics that target Type 2 inflammation to treat COPD with increased peripheral blood eosinophils

open access: yesHeliyon, 2022
Background and aims: Biologics that target Type 2 inflammation are effective in reducing exacerbations of severe asthma. We conducted a systematic review and integrated analysis of the efficacy and safety of these biologics in chronic obstructive ...
Hiroshi Ohnishi   +2 more
doaj   +1 more source

Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study

open access: yesBMC Pulmonary Medicine, 2020
Background Benralizumab, an anti-interleukin-5 (IL-5) receptor α monoclonal antibody, significantly reduces the number of annual exacerbations and oral corticosteroid (OCS) maintenance doses for patients with severe eosinophilic asthma (SEA).
Takanori Numata   +10 more
doaj   +1 more source

Eosinophils depletion therapy for severe asthma management following favorable response to mepolizumab

open access: yesRespiratory Medicine Case Reports, 2019
We described three severe asthmatics whose asthma symptoms were rapidly improved by benralizumab following favorable response to mepolizumab. Benralizumab-induced eosinophil depletion contributed to clinical improvement of severe asthma after mepolizumab-
Osamu Matsuno, Seijiro Minamoto
doaj   +1 more source

Monoclonal antibodies in type 2 asthma : a systematic review and network meta-analysis [PDF]

open access: yes, 2019
Since novel treatments to target eosinophilic inflammation in Type 2 asthma are emerging, we aimed to evaluate and meta-analyze the efficacy of monoclonal antibodies to reduce exacerbation rate.
De Feyter, Silke   +4 more
core   +1 more source

Eosinophilic cystitis refractory to steroids successfully treated with benralizumab: A case report

open access: yesFrontiers in Allergy, 2023
We report a case of a 66-year-old male diagnosed with refractory to oral corticosteroids eosinophilic cystitis (EoC). Hematuria was the first and only sign of the disease that was otherwise asymptomatic, and the only abnormal lab finding he had was ...
George N. Konstantinou   +1 more
doaj   +1 more source

Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population [PDF]

open access: yes, 2017
Acknowledgments The authors thank Derek Skinner (Cambridge Research Support Ltd, Oakington, Cambridge, UK) for assistance with data extraction.Peer reviewedPublisher ...
Gibson, Danny   +6 more
core   +1 more source

Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma.

open access: yesPLoS ONE, 2021
PurposeTo characterize the clinical phenotypes of severe eosinophilic asthma based on early responsiveness to benralizumab in terms of forced expiratory volume in 1 second (FEV1) improvement.Patients and methodsSixty-four participants diagnosed with ...
Hideyasu Yamada   +10 more
doaj   +1 more source

Eosinophil Apoptosis and Clearance in Asthma [PDF]

open access: yes, 2013
Peer reviewedPublisher ...
Bickham U.R.   +9 more
core   +3 more sources

Home - About - Disclaimer - Privacy